Deep Genomics: Business Overview, Financials & Competitive Analysis
Deep Genomics is an AI-powered platform for RNA biology that accelerates genetic therapy discovery. The company focuses on untangling complex RNA data to identify novel targets and therapeutic candidates for genetic c...
Cyborg Score thesis
Deep Genomics is a capital-efficient, AI-first biotech that is leveraging machine learning to compress drug discovery timelines...
Read the full analyst-debate transcript →Get the Latest Deep Genomics Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeDeep Genomics Overview
Pro stress-test →Deep Genomics is an AI-powered platform for RNA biology that accelerates genetic therapy discovery. The company focuses on untangling complex RNA data to identify novel targets and therapeutic candidates for genetic conditions, leveraging a proprietary AI platform including its flagship BigRNA model that uses machine learning to analyze vast RNA biology data. This positions Deep Genomics as a pioneer in applying advanced AI to address previously intractable genetic diseases through RNA-based therapeutics.
Strategic Profile
Pro stress-test →The company's AI platform accelerates early-stage drug discovery and the design of RNA-based therapies. Deep Genomics ranks 9th among 788 active AI-drug discovery competitors and stands 4th in total funding within its competitive set. With significant venture backing and a focused platform approach, the company is positioned as a leading pure-play AI drug discovery platform for rare and genetic diseases where RNA therapeutics can address unmet clinical needs.
Competitive Landscape
Pro stress-test →Competitors include OneThree Biotech, Caris Life Sciences, Phenomic AI, Genesis Molecular AI, and Stoke Therapeutics. Other notable players in AI drug discovery include Atomwise (University of Toronto-affiliated) and UK-based Exscientia (also SoftBank-backed); Deep Genomics' differentiator is that its AI can program RNA therapy for almost any gene at any genetic position. Deep Genomics is the most focused on RNA-specific drug discovery and design.
Industry Context
Deep Genomics operates in Clinical AI & Drug Discovery.
Key facts
Founded: 2014 · Headquarters: Toronto, Canada · Employees: 108 (as of April 2026) · Revenue: Not publicly disclosed · Market cap: N/A